Niowave

Niowave is a private, industry-leading supplier of medical radioisotopes essential for targeted alpha therapies in oncology. The company leverages its proprietary superconducting electron linear accelerator technology and advanced radiochemistry to produce isotopes like Ac-225, addressing a critical supply bottleneck in the radiopharmaceutical sector. With deep technical expertise built over two decades, Niowave operates under cGMP standards and aims to enable the clinical development and commercialization of novel cancer treatments. Its integrated model of designing, building, and operating its own accelerator infrastructure provides full control over production quality and scalability.

Proprietary superconducting electron linear accelerators and advanced radiochemistry for the production of medical radioisotopes, including Actinium-225.

Niowave competes with other isotope producers like NorthStar Medical Radioisotopes, BWXT, Orano Med, and legacy reactor-based suppliers. The competitive landscape is defined by the race to establish scalable, cost-effective, and regulatory-approved production methods for high-demand therapeutic isotopes like Ac-225.